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The Pharmacological Treatment of Ischemic Stroke goes beyond tPa: 
Edaravone, an Already Commercialized Promise. 
Patophisiology and therapeutic targetsIntroduction
Ischemic stroke is the third leading cause of death in industrialized countries and the most frequent
cause of permanent disability in adult worldwide. As expected, disability involves tremendous
personal and financial cost to the individual, the family and the health care system.
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o Edaravone belongs to phenol
compounds
o Lipofhilic
o Low molecular weight
Able to cross the 
blood brain barrier
Illustration adapted from Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of
apoptosis in disease. Aging(Albany NY). 2012;4(5):330–49.Modified by Bono Miralles, Bea.
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tPA
edaravone
o Reduced edema 
o Less white matter tissue rate
o Inhibition of tPA-induced hemorrhagic
transformation
o Less blood-brain barrier damage and oxidative
stress 
Edaravone strengthen thrombolysis when administrated
with tpA, thus increasing benefits of early, but not late, tPA
therapy
Safety Tolerability Efficacy Indications
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o the amount of 
potential therapeutic 
targets is immense.
o many strategies 
proposed
o necessary to promote 
research in this field
The successful 
treatment of 
acute 
ischemic 
stroke
Thanks to the efforts made by some researches, there are some drugs in a very advanced stage likely
to become a reality.
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Synergy of combined tPA – Edaravone therapy
Europ, why not? 
Objectives
o Make an overview of the main pharmacological treatments for ischemic stroke.
o Provide a general view of the main therapies that are in process of investigation, giving special
attention to those that are likely to hit the market in the near future.
o To focus on edaravone, the only free radical scavenger that has provided clinical evidence for
therapeutic effects on ischemic stroke.
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